Inflammation

DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety

Monday, September 27, 2021 - 9:30pm

DermTech , Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open , an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima.

Key Points: 
  • DermTech , Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open , an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima.
  • The San Diego Open, held at the Barnes Tennis Center from September 27 through October 3, 2021, features a 28-player singles draw and a 16-team doubles draw.
  • As a company deeply rooted in the San Diego community, DermTech is honored to sponsor the San Diego Open and kick-off a great partnership with Brandon Nakashima, said John Dobak, M.D., CEO of DermTech.
  • We are looking forward to participating in this fantastic tennis event and bringing recognition to the importance of sun safety and skin health, in general.

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

Monday, September 27, 2021 - 9:00pm

is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Key Points: 
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers and Treatment Resistant Depression(Xpro), and NASH (LIVNate).
  • Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

Monday, September 27, 2021 - 5:30pm

This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.

Key Points: 
  • This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021

Monday, September 27, 2021 - 5:00pm

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Key Points: 
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
  • In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Monday, September 27, 2021 - 3:30pm

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
  • We are thrilled to be recognized by Fierce Biotech among the industrys leading innovators, reflecting the potential of our novel pipeline and approach.
  • Speaking with this years class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Energy, Focus, Intention: New CBD Strength Gummy from House of Wise Empowers Women to Reclaim Their Workout Routines, Make the Most of Time Spent in Motion

Monday, September 27, 2021 - 3:32pm

MIAMI, Sept. 27, 2021 /PRNewswire/ -- Today, CBD and personal wellness brand House of Wise announces a new vertical in its line of vegan CBD products: Strength .

Key Points: 
  • MIAMI, Sept. 27, 2021 /PRNewswire/ -- Today, CBD and personal wellness brand House of Wise announces a new vertical in its line of vegan CBD products: Strength .
  • "House of Wise makes products that help me optimize the way I feel at work, at rest, and now at the gym.
  • House of Wise empowers women to take control of their lives while working to shatter the stigmas and double standards women face today.
  • She is a leader and advocate breaking down stigmas and stereotypes surrounding CBD, cannabis, and the role of women in our society today.

Lupus Foundation of America Awards Four Grants to Early Career Scientists, Supporting Crucial Areas of Research and Growth in the Field

Monday, September 27, 2021 - 3:00pm

WASHINGTON, Sept. 27, 2021 /PRNewswire/ --The Lupus Foundation of America is proud to announce the recipients of the 2021 Gary S. Gilkeson Career Development Award (CDA), a two-year grant focusing on critical lupus research while supporting early career scientists at the beginning of their careers, helping to ensure continued growth in the lupus research field.

Key Points: 
  • WASHINGTON, Sept. 27, 2021 /PRNewswire/ --The Lupus Foundation of America is proud to announce the recipients of the 2021 Gary S. Gilkeson Career Development Award (CDA), a two-year grant focusing on critical lupus research while supporting early career scientists at the beginning of their careers, helping to ensure continued growth in the lupus research field.
  • This year's grantees will focus their research on cognition, pediatric lupus, lupus nephritis and B-cell therapies.
  • Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.
  • Learn more about the Lupus Foundation of America at lupus.org .

Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing

Monday, September 27, 2021 - 2:00pm

On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.

Key Points: 
  • On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.
  • Following TSOI's initial research, there have been multiple studies published in peer-reviewed journals by independent academic institutions supporting the individual ingredients in QuadraMune, which are listed below by ingredients.
  • To our knowledge, QuadraMune is the only nutraceutical on the market with this level of independent scientific support for its potential use in COVID-19.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

Monday, September 27, 2021 - 1:24pm

Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.

Key Points: 
  • Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.
  • Under the terms of the agreement, Intract has granted Bio-Thera a worldwide license to Intracts oral biologics drug delivery platform for a single undisclosed mAb product.
  • Intract will receive an undisclosed upfront payment, with potential development and commercial milestone payments along with royalties on product sales.
  • Intracts oral biologics delivery platform includes Soteria a technology which protects proteins such as mAbs from degradation in the intestinal lumen.

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Monday, September 27, 2021 - 1:00pm

Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.

Key Points: 
  • Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.
  • During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development.
  • Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development and manufacturing services for companies around the world.
  • Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing info@minnetronixneuro.com .